(Q36482832)

English

Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

Clostridium difficile

0 references

1 reference

based on heuristic

inferred from title

author name string

Efi Kokkotou

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Alan C Moss

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Athanasios Michos

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Daniel Espinoza

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jeffrey W Cloud

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Nasima Mustafa

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Michael O'Brien

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Charalabos Pothoulakis

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Ciarán P Kelly

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

14 January 2008

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

52

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1121-1126

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Narrative review: the new epidemic of Clostridium difficile-associated enteric disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Recurrent clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

An epidemic, toxin gene-variant strain of Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Treatment of Clostridium difficile-associated disease: old therapies and new strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Risk factors for recurrence of Clostridium difficile-associated diarrhea in the elderly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Epidemiology of Clostridium difficile-associated infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Clostridium difficile colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

30 September 2017

In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

28 June 2018

Quebec to report on Clostridium difficile in 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

28 June 2018

The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Revised nomenclature of Clostridium difficile toxins and associated genes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258528

21 September 2018

Clostridium difficile

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clostridium difficile-associated diarrhoea in hospitalised patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18195066

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.01143-07

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36482832&oldid=1635123941"